|
業務類別
|
Biotechnology |
|
業務概覽
|
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD. |
| 公司地址
| 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472 |
| 電話號碼
| +1 833 393-7646 |
| 傳真號碼
| +1 617 926-5050 |
| 公司網頁
| https://www.eyepoint.bio |
| 員工數量
| 214 |
| Dr. Jay S. Duker, M.D. |
Director, President and Chief Executive Officer |
美元 696.25K |
27/04/2026 |
| Mr. George O. Elston |
Executive Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 527.68K |
27/04/2026 |
| Dr. Ramiro Ribeiro, M.D.,PhD |
Chief Medical Officer |
美元 505.01K |
27/04/2026 |
|
|
| Dr. Goran A. Ando, M.D. |
Chairman of the Board |
27/04/2026 |
| Ms. Karen Zaderej |
Independent Director |
27/04/2026 |
| Dr. Jay S. Duker, M.D. |
Director, President and Chief Executive Officer |
27/04/2026 |
| Mr. Fred Hassan |
Independent Director |
27/04/2026 |
| Ms. Wendy F. DiCicco |
Independent Director |
27/04/2026 |
| Mr. Stuart M. Duty |
Independent Director |
27/04/2026 |
| Ms. Nancy S. Lurker |
Vice Chairman of the Board |
27/04/2026 |
| Dr. Reginald J. Sanders, M.D. |
Director |
27/04/2026 |
| Dr. John B. Landis, PhD |
Director |
27/04/2026 |
|
|
|
|
